Algorae executes Licence & Supply Agreement with Umedica
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Algorae Pharmaceuticals Limited has announced the execution of a Memorandum of Understanding and a Licence & Supply Agreement with Umedica Laboratories for the Australian pharmaceutical market. Under these agreements, AlgoraeRx will act as Umedica's exclusive importer and distributor in Australia for a range of products, while also obtaining marketing authorization for commercialization under its own brand. The product dossier has been submitted for regulatory approval to the Therapeutic Goods Administration. This partnership aims to enhance Algorae's product pipeline and strengthen its strategy in the Australian market.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Algorae Pharmaceuticals Limited on 6ix
Story so far
Earlier from Algorae Pharmaceuticals
- Peter Mac partners with Algorae on 3rd AI validation program
- Notice of Annual General Meeting/Proxy Form
- Change of Director's Interest Notice - DH
- Date of AGM and Closing Date for Director Nominations
- Notification of cessation of securities - 1AI
Later from Algorae Pharmaceuticals
- Updated Securities Trading Policy
- Quarterly Activities Report and Appendix 4C Cash Flow Report
- Corporate Presentation
Follow Algorae Pharmaceuticals into a list and get an email when it puts out news.
Follow Algorae Pharmaceuticals